Table 1 Baseline characteristics
From: Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study
Characteristic | MG total | OMG | MGFA IIa | MGFA II + IIIb | Healthy controls |
|---|---|---|---|---|---|
N | 40 | 7 | 18 | 15 | 23 |
Age, y, mean (SD) | 55.7 (18.4) | 58.3 (19.2) | 52.1 (16.0) | 58.7 (21.2) | 52.0 (16.2) |
Female Sex, n (%) | 17 (43.6) | 2 (28.6) | 8 (44.4) | 7 (46.7) | 11 (47.8) |
AChR-ab, (%) | 34 (85) | 5 (71.4) | 16 (88.9) | 13 (86.7) | n.a |
QMG-score, mean (SD) | 7.4 (6.3) | 2.9 (3.0) | 5.7 (5.4) | 11.1 (6.5) | n.a. |
Disease duration, y, median (IQR) | 5.5 (2.25–14.5) | 2.0 (2.0–3.0) | 6.5 (3.75–30.25) | 8.0 (2.0–13.0) | n.a. |
Medication | n.a. | ||||
ChE-Inhibitors, n (%) | 31 (77.5) | 5 (83.3) | 14 (77.8) | 12 (80) | n.a. |
Steroids, n (%) | 22 (55.0) | 3 (50) | 9 (50) | 10 (66.7) | n.a. |
Immunosuppression, n (%) | 25 (62.5) | 1 (16.7) | 12 (66.7) | 12 (80) | n.a. |